DOCSLIB.ORG

Cayman PL 16-17

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cayman PL 16-17 Cayman Chemical - 2016-17 Catalog Description Pack Size Supplier Price(RS) 100000 Optineurin (C-Term) Polyclonal Antibody 1 ea Cayman 40430 100002 Optineurin (INT) Polyclonal Antibody 500 µl Cayman 40430 100011 CD36 Polyclonal Antibody 1 ea Cayman 40430 100012 Vitellogenin (Japanese medaka) Monoclonal Antibody (Clone CK- 100 µl Cayman 44827 4B3) 100012 Vitellogenin (Japanese medaka) Monoclonal Antibody (Clone CK- 500 µl Cayman 172782 4B3) 100017 Zona Radiata (salmon) Monoclonal Antibody (Clone MN-8C4) 100 µl Cayman 44827 100017 Zona Radiata (salmon) Monoclonal Antibody (Clone MN-8C4) 500 µl Cayman 172782 100018 Zona Radiata (salmon) Monoclonal Antibody (Clone MN-7F2) 100 µl Cayman 44827 100018 Zona Radiata (salmon) Monoclonal Antibody (Clone MN-7F2) 500 µl Cayman 172782 100019 BLT1 Receptor Polyclonal Antiserum 1 ea Cayman 40430 100020 Zona Radiata (salmon) Monoclonal Antibody (Clone MN-2B4) 100 µl Cayman 44827 100020 Zona Radiata (salmon) Monoclonal Antibody (Clone MN-2B4) 500 µl Cayman 172782 100022 Hepsin Polyclonal Antibody (aa 241-260) 500 µl Cayman 40430 100023 Prostaglandin I Synthase (mouse) Polyclonal Antibody 1 ea Cayman 40430 100025 5-OxoETE Receptor Polyclonal Antibody 500 µl Cayman 40430 100027 SOAT-2/ACAT-2 Polyclonal Antibody 1 ea Cayman 40430 100028 SOAT-1/ACAT-1 Polyclonal Antibody 1 ea Cayman 40430 100029 β-Catenin Polyclonal Antibody 500 µl Cayman 40430 100030 Endothelial Lipase Polyclonal Antibody 500 µl Cayman 40430 100033 Vitellogenin (Japanese medaka) Monoclonal Antibody (Clone CK- 100 µl Cayman 44827 1H11) 100033 Vitellogenin (Japanese medaka) Monoclonal Antibody (Clone CK- 500 µl Cayman 172782 1H11) 100034 Goat Anti-COX-2 (human) Affinity-Purified Polyclonal Antibody 1 ea Cayman 40430 100035 Monoacylglycerol Lipase Polyclonal Antibody 1 ea Cayman 40430 10004301 Goat Anti-Rabbit IgG HRP 1 ea Cayman 17598 10004302 Goat Anti-Mouse IgG HRP 1 ea Cayman 16357 10004303 11β-Hydroxysteroid Dehydrogenase (Type 1) Polyclonal Antibody 1 ea Cayman 40430 10004337 Prostaglandin D Synthase (hematopoietic-type; human) Polyclonal 1 ea Cayman 40430 Antibody 10004342 Prostaglandin D Synthase (lipocalin-type; human) Monoclonal 1 ea Cayman 40430 Antibody (Clone 10A5) 10004344 Prostaglandin D Synthase (lipocalin-type; mouse) Polyclonal 1 ea Cayman 40430 Antibody 10004345 Prostaglandin D Synthase (hematopoietic-type; human) Monoclonal 1 ea Cayman 40430 Antibody (Clone 2A5) 1 Cayman Chemical - 2016-17 10004348 Prostaglandin D Synthase (hematopoietic-type; mouse) Polyclonal 1 ea Cayman 40430 Antiserum 10004349 Prostaglandin D Synthase (hematopoietic-type; mouse) Monoclonal 1 ea Cayman 40430 Antibody (Clone 7H4) 10004350 Prostaglandin E Synthase-1 (microsomal) Monoclonal Antibody 1 ea Cayman 40430 (Clone 6C6) 10004442 Vitellogenin (stickleback) Polyclonal Antibody (GA-306) 100 µl Cayman 44827 10004442 Vitellogenin (stickleback) Polyclonal Antibody (GA-306) 500 µl Cayman 172782 10004452 TP Receptor (human) Polyclonal Antibody 1 ea Cayman 40430 10004454 15-Lipoxygenase-2 Polyclonal Antibody 1 ea Cayman 40430 10004549 11β-Hydroxysteroid Dehydrogenase (Type 2) Polyclonal Antibody 1 ea Cayman 40430 10004597 CD45 Monoclonal Antibody (Clone BRA-55) 1 ea Cayman 40430 10004599 CD4 Monoclonal Antibody (Clone RIV7) 1 ea Cayman 40430 10004600 Cytokeratin Monoclonal Antibody (Clone C-11) 1 ea Cayman 40430 10004604 CD95 Monoclonal Antibody (Clone IPO-4) 1 ea Cayman 40430 10004715 CD8 Monoclonal Antibody (Clone RIV11) 1 ea Cayman 40430 10004716 CD19 Monoclonal Antibody (Clone CB19) 1 ea Cayman 40430 10004718 CD37 Monoclonal Antibody (Clone IPO-24) 1 ea Cayman 34102 10004804 CD150 Monoclonal Antibody (Clone IPO-3) 1 ea Cayman 33357 10004805 PCNA Monoclonal Antibody (Clone IPO-38) 1 ea Cayman 40430 10004806 p53 Monoclonal Antibody (Clone BP53-12) 1 ea Cayman 40430 10004807 p53 (Phospho-Ser392) Polyclonal Antibody 1 ea Cayman 63334 10004835 CD34 Monoclonal Antibody (Clone ICO-115) 1 ea Cayman 34722 10004837 CD27 Monoclonal Antibody (Clone 203.6) 1 ea Cayman 39810 10004840 LPA3 Polyclonal Antibody 1 ea Cayman 40430 10004886 CRTH2/DP2 Receptor (N-Term) Polyclonal Antibody 1 ea Cayman 40430 10004942 Nod2 Monoclonal Antibody (Clone 2D9) 1 ea Cayman 40430 10004943 PEPCK Polyclonal Antibody 1 ea Cayman 40430 10004944 FABP4 Polyclonal Antibody 1 ea Cayman 40430 10005059 PTEN Polyclonal Antibody 500 µl Cayman 40430 10005190 EAF2 Polyclonal Antibody 1 ea Cayman 40430 10005228 S1P1 Polyclonal Antibody 1 ea Cayman 40430 10005258 GPx4 Polyclonal Antibody 1 ea Cayman 42912 10005260 Serine Palmitoyltransferase Polyclonal Antibody 1 ea Cayman 42912 10005280 LPA1 Polyclonal Antibody 1 ea Cayman 40430 10005292 Atherosclerosis Product Pack 1 ea Cayman 63511 10005375 Lysophospholipase D Polyclonal Antibody 1 ea Cayman 40430 10005517 Doppel Polyclonal Antibody 1 ea Cayman 40430 10005518 IP Receptor (human) Polyclonal Antibody 1 ea Cayman 40430 10006170 DMPO Nitrone Adduct Polyclonal Antiserum 1 ea Cayman 45394 10006283 PINK1 Polyclonal Antibody 1 ea Cayman 40430 10006355 Melanocortin-4 Receptor Polyclonal Antibody 1 ea Cayman 40430 10006371 Hormone-Sensitive Lipase Polyclonal Antibody 500 µl Cayman 40430 10006373 S1P3 Polyclonal Antibody 1 ea Cayman 40430 10006409 Adipose Triglyceride Lipase Polyclonal Antibody 1 ea Cayman 40430 10006421 HIF-1α (C-Term) Polyclonal Antibody 1 ea Cayman 40430 10006588 Goat Anti-Rabbit IgG FITC 1 ea Cayman 17598 2 Cayman Chemical - 2016-17 10006590 CB1 Receptor (C-Term) Polyclonal Antibody 1ea Cayman 42912 10006617 Goat Anti-Mouse (IgG+IgM) FITC 1 ea Cayman 16357 10006778 Nitrotyrosine (Peptide) Polyclonal Antibody 500 µl Cayman 36708 10006822 Sphingosine Kinase 1 Polyclonal Antibody 1 ea Cayman 40430 10006966 Nitrotyrosine Monoclonal Antibody - Biotinylated 100 µg Cayman 44153 10007002 CRTH2/DP2 Receptor (C-Term) Polyclonal Antibody 1 ea Cayman 40430 10007048 Vitellogenin (bird) Monoclonal Antibody (ND-3C3) 100 µl Cayman 49613 10007048 Vitellogenin (bird) Monoclonal Antibody (ND-3C3) 500 µl Cayman 194321 10007049 Vitellogenin (bird) Monoclonal Antibody (ND-3G6) 100 µl Cayman 49613 10007049 Vitellogenin (bird) Monoclonal Antibody (ND-3G6) 500 µl Cayman 194321 10007143 Vitellogenin (alligator) Monoclonal Antibody (ND-1E8) 100 µL Cayman 49613 10007143 Vitellogenin (alligator) Monoclonal Antibody (ND-1E8) 500 µL Cayman 194321 10007185 PCSK9 (human) Polyclonal Antibody 1 ea Cayman 40430 10007191 PH Domain Leucine-rich Repeat Protein Phosphatase 1 Polyclonal 1 ea Cayman 40430 Antibody 10007205 FFAR1 (GPR40) Polyclonal Antibody 1 ea Cayman 40430 10007660 GPR35 Polyclonal Antibody 1 ea Cayman 40430 10007663 SREBP-2 Polyclonal Antibody 1 ea Cayman 42912 10007665 LDL Receptor Polyclonal Antibody 1 ea Cayman 40430 10007681 Serum Retinol Binding Protein 4 Polyclonal Antibody 500 µl Cayman 40430 10007820 5-Lipoxygenase (Phospho-Ser523) Polyclonal Antibody 1 ea Cayman 63334 10008207 IGFBP5 Polyclonal Antibody 500 µl Cayman 40430 10008463 ApoA1 Polyclonal Antibody 1 ea Cayman 40430 10008811 PCSK9 (mouse) Polyclonal Antibody 1 ea Cayman 40430 10008856 GnRHa Polyclonal Antibody 200 µl Cayman 79608 10009025 Prion Protein Monoclonal Antibody (Clone 2G11) 1 ea Cayman 68120 10009030 Prion Protein Monoclonal Antibody (Clone 11C6) 1 ea Cayman 68120 10009034 Prion Protein Monoclonal Antibody (Clone BAR 221) 1 ea Cayman 68120 10009035 Prion Protein Monoclonal Antibody (Clone BAR 224) 1 ea Cayman 60303 10009036 Prion Protein Monoclonal Antibody (Clone BAR 233) 1 ea Cayman 68120 10009037 Prion Protein Monoclonal Antibody (Clone BAR 236) 1 ea Cayman 68120 10009323 LCAT Polyclonal Antibody 500 µl Cayman 40430 10009370 Dopamine β-hydroxylase (C-Term; human) Polyclonal Antibody 1 ea Cayman 63334 10009371 Dopamine β-hydroxylase (N-Term; human) Polyclonal Antibody 1 ea Cayman 63334 10009372 Dopamine Transporter (C-Term) Polyclonal Antibody 1 ea Cayman 63334 10009373 Dopamine Transporter (Extracellular Loop 2) Polyclonal Antibody 1 ea Cayman 63334 10009374 GSK3β (Phospho-Ser9) Polyclonal Antibody 1 ea Cayman 63334 10009396 Tryptophan Hydroxylase Polyclonal Antibody 1 ea Cayman 63334 10009397 Tryptophan Hydroxylase (Phospho-Ser58) Polyclonal Antibody 1 ea Cayman 63334 10009398 Tryptophan Hydroxylase (Phospho-Ser260) Polyclonal Antibody 1 ea Cayman 63334 10009399 Glycine Receptor Polyclonal Antibody 1 ea Cayman 63334 10009400 Gap-43 (Phospho-Ser41) Polyclonal Antibody 1 ea Cayman 63334 10009410 ATF2 (Phospho-Ser490,498) Polyclonal Antibody 100 µl Cayman 63334 3 Cayman Chemical - 2016-17 10009411 Ribosomal S6 Kinase 2 Polyclonal Antibody 1 ea Cayman 63334 10009413 Tyrosine Hydroxylase (Phospho-Ser31) Polyclonal Antibody 1 ea Cayman 63334 10009414 Tyrosine Hydroxylase (Phospho-Ser40) Polyclonal Antibody 1 ea Cayman 63334 10009504 Raf-1 (Phospho-Ser301) Polyclonal Antibody 1 ea Cayman 63334 10009505 Raf-1 (Phospho-Ser642) Polyclonal Antibody 1 ea Cayman 63334 10009506 PSD95 Polyclonal Antibody 1 ea Cayman 63334 10009517 MEK1 (Phospho-Thr386) Polyclonal Antibody 1 ea Cayman 63334 10009518 MEK1 (Phospho-Thr292) Polyclonal Antibody 1 ea Cayman 63334 10009759 NMDA Receptor NR2B Subunit (Phospho-Tyr1252) Polyclonal 1 ea Cayman 63334 Antibody 10009760 NMDA Receptor NR2B Subunit (Phospho-Tyr1336) Polyclonal 1 ea Cayman 63334 Antibody 10009761 NMDA Receptor NR2B Subunit (Phospho-Tyr1472) Polyclonal 1 ea Cayman 63334 Antibody 10009762 Progesterone Receptor (Phospho-Ser190) Monoclonal Antibody 1 ea Cayman 63334 10009763 Progesterone Receptor (Phospho-Ser294) Monoclonal Antibody 1 ea Cayman 63334 10009785 Dynamin (Phospho-Ser774) Polyclonal Antibody 1 ea Cayman 63334 10009786
Load more

Recommended publications
  • Annual Conference Online 2021
    CANDIDAANNUAL CONFERENCEAND ONLINECANDIDIASIS 2021 2021 21–27 March 2021 POSTER ABSTRACT BOOK #Candida2021 001A Candida auris gene expression: modulation upon caspofungin treatment Lysangela Alves1, Rafaela Amatuzzi1, Daniel Zamith-Miranda2, Sharon Martins1, Joshua Nosanchuk2 1Carlos Chagas Institute, Curitiba, Brazil. 2Departments of Medicine (Division of Infectious Diseases) and Microbiology and Immunology, Albert Einstein College of Medicine, New York, USA Abstract Candida auris has emerged as a serious worldwide threat by causing invasive infections in humans that are frequently resistant to one or more conventional antifungal medications, resulting in high mortality rates. Against this backdrop, health warnings around the world have focused efforts on understanding C. auris fungal biology and effective treatment approaches to combat this fungus. To date, there is little information about C. auris gene expression regulation in response to antifungal treatment. Our integrated analyses focused on the comparative transcriptomics of C. auris in the presence and absence of caspofungin as well as a detailed analysis of the yeast’s extracellular vesicle (EV)-RNA composition. The results showed that genes coding oxidative stress response, ribosomal proteins, cell wall, and cell cycle were significantly up-regulated in the presence of caspofungin, whereas transcriptional regulators and proteins related to nucleus were down-regulated. The mRNAs in the EVs were associated with the stress responses induced by caspofungin and the ncRNA content of the EVs shifted during caspofungin treatment. Altogether, the results provide further insights into the fungal response to caspofungin and demonstrate that analyses of C. auris growth under antifungal stress can elucidate resistance and survival mechanisms of this fungus in response to medical therapy.
    [Show full text]
  • 615 Neuroscience-Cayman-Bertin
    Thomas G. Brock, Ph.D. Introduction to Neuroscience In our first Biology classes, we learned that lipids form the membranes around cells. For many students, interests quickly moved to the intracellular constituents ‘that really matter’, or to how cells or systems work in health and disease. If there was further thought about lipids, it might have been limited to more personal issues, like an expanding waistline. It was easy to forget about lipids in the complexities of, say, Alzheimer’s Disease, where tau protein is hyperphosphorylated by a host of kinases before forming neurofibrillary tangles and amyloid precursor protein is processed by assorted secretases, ultimately aggregating to form neurodegenerating plaques. What possible role could lipids have in all this? After all, lipids just form the membranes around cells. Fortunately, neuroscientists study complex systems. Whether working at the molecular, cellular, or organismal level, the research focus always returns to the intricately interconnected bigger picture. Perhaps surprisingly, lipids keep emerging as part of the bigger picture. At least, the smaller lipids do. Many of the smaller lipids, including the cannabinoids and eicosanoids, act as paracrine hormones, modulating cell functions in a receptor-mediated fashion. In this sense, they are rather like the peptide hormones in their diversity and actions. In the neurosystem, this means that these signaling lipids determine if synapses fire or not, when cells differentiate or die, and whether tissues remain healthy or become inflamed. Returning to the question posed above about lipids in Alzheimer’s, these mediators have roles at many levels in the course of the disease, as presented in an article on page 42 of this catalog.
    [Show full text]
  • Glossary Terms
    Glossary Terms € 1584 5W6 5501 a 7181, 12203 5’UTR 8126 a-g Transformation 6938 6Q1 5500 r 7181 6W1 5501 b 7181 a 12202 b-b Transformation 6938 A 12202 d 7181 AAV 10815 Z 1584 Abandoned mines 6646 c 5499 Abiotic factor 148 f 5499 Abiotic 10139, 11375 f,b 5499 Abiotic stress 1, 10732 f,i, 5499 Ablation 2761 m 5499 ABR 1145 th 5499 Abscisic acid 9145 th,Carnot 5499 Absolute humidity 893 th,Otto 5499 Absorbed dose 3022, 4905, 8387, 8448, 8559, 11026 v 5499 Absorber 2349 Ф 12203 Absorber tube 9562 g 5499 Absorption, a(l) 8952 gb 5499 Absorption coefficient 309 abs lmax 5174 Absorption 309, 4774, 10139, 12293 em lmax 5174 Absorptivity or absorptance (a) 9449 μ1, First molecular weight moment 4617 Abstract community 3278 o 12203 Abuse 6098 ’ 5500 AC motor 11523 F 5174 AC 9432 Fem 5174 ACC 6449, 6951 r 12203 Acceleration method 9851 ra,i 5500 Acceptable limit 3515 s 12203 Access time 1854 t 5500 Accessible ecosystem 10796 y 12203 Accident 3515 1Q2 5500 Acclimation 3253, 7229 1W2 5501 Acclimatization 10732 2W3 5501 Accretion 2761 3 Phase boundary 8328 Accumulation 2761 3D Pose estimation 10590 Acetosyringone 2583 3Dpol 8126 Acid deposition 167 3W4 5501 Acid drainage 6665 3’UTR 8126 Acid neutralizing capacity (ANC) 167 4W5 5501 Acid (rock or mine) drainage 6646 12316 Glossary Terms Acidity constant 11912 Adverse effect 3620 Acidophile 6646 Adverse health effect 206 Acoustic power level (LW) 12275 AEM 372 ACPE 8123 AER 1426, 8112 Acquired immunodeficiency syndrome (AIDS) 4997, Aerobic 10139 11129 Aerodynamic diameter 167, 206 ACS 4957 Aerodynamic
    [Show full text]
  • Research Publications by DISTINCTIONS Any Scientist of Pakistan in Last 10 Year and SERVICES  Secretary General, the Chemical Society of Pakistan
    CV and List of Publications PROF. DR. MUHAMMAD IQBAL CHOUDHARY (Hilal-e-Imtiaz, Sitara-e-Imtiaz, Tamgha-ei-Imtiaz) International Center for Chemical and Biological Sciences (H. E. J. Research Institute of Chemistry, Dr. Panjwani Center for Molecular Medicine and Drug Research) University of Karachi, Karachi-75270 Pakistan Tel: (92-21) 34824924, 34824925 Fax: 34819018, 34819019 E-mail: [email protected] Web Page: www.iccs.edu Biodata and List of Publications Pag No. 2 MUHAMMAD IQBAL CHOUDHARY (Hilal-e-Imtiaz, Sitara-e-Imtiaz, Tamgha-e-Imtiaz) D-131, Phase II, D. O. H. S., Malir Cant., Karachi-75270, Pakistan Ph.: 92-21-4901110 MAILING INTERNATIONAL CENTER FOR CHEMICAL AND BIOLOGICAL SCIENCES ADDRESS (H. E. J. Research Institute of Chemistry Dr. Panjwani Center for Molecular Medicine and Drug Research) University of Karachi Karachi-74270, Pakistan Tel: (92-21) 34824924-5 Fax: (92-21) 34819018-9 Email: [email protected] Web: www.iccs.edu DATE OF BIRTH September 11, 1959 (Karachi, Pakistan) EDUCATION Doctor of Science (D.Sc.) (University of Karachi ) 2005 Ph.D. (Organic Chemistry) 1987 H. E. J. Research Institute of Chemistry University of Karachi, Karachi-75270, Pakistan Thesis Title: "The Isolation and Structural Studies on Some Medicinal Plants of Pakistan, Buxus papillosa, Catharanthus roseus, and Cissampelos pareira." M.Sc. (Organic Chemistry) 1983 University of Karachi, Karachi-75270, Pakistan B.Sc. (Chemistry, Biochemistry, Botany) 1980 University of Karachi, Karachi-75270, Pakistan AWARDS & Declared as the top most scientist (Number 1) among 1,650 HONORS scientists of Pakistan in all disciplines / fields of science and technology (year 2012) by the Pakistan Council for Science and Technology (Ministry of Science and Technology), Pakistan.
    [Show full text]
  • Potential Drug Candidates Underway Several Registered Clinical Trials for Battling COVID-19
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 20 April 2020 doi:10.20944/preprints202004.0367.v1 Potential Drug Candidates Underway Several Registered Clinical Trials for Battling COVID-19 Fahmida Begum Minaa, Md. Siddikur Rahman¥a, Sabuj Das¥a, Sumon Karmakarb, Mutasim Billahc* aDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi-6205, Bangladesh bMolecular Biology and Protein Science Laboratory, University of Rajshahi, Rajshahi-6205, Bangladesh cProfessor Joarder DNA & Chromosome Research Laboratory, University of Rajshahi, Rajshahi-6205, Bangladesh *Corresponding Author: Mutasim Billah, Professor Joarder DNA & Chromosome Research Laboratory, University of Rajshahi, Rajshahi, Bangladesh Corresponding Author Mail: [email protected] ¥Co-second author Abstract The emergence of new type of viral pneumonia cases in China, on December 31, 2019; identified as the cause of human coronavirus, labeled as "COVID-19," took a heavy toll of death and reported cases of infected people all over the world, with the potential to spread widely and rapidly, achieved worldwide prominence but arose without the procurement guidance. There is an immediate need for active intervention and fast drug discovery against the 2019-nCoV outbreak. Herein, the study provides numerous candidates of drugs (either alone or integrated with another drugs) which could prove to be effective against 2019- nCoV, are under different stages of clinical trials. This review will offer rapid identification of a number of repurposable drugs and potential drug combinations targeting 2019-nCoV and preferentially allow the international research community to evaluate the findings, to validate the efficacy of the proposed drugs in prospective trials and to lead potential clinical practices. Keywords: COVID-19; Drugs; 2019-nCoV; Clinical trials; SARS-CoV-2 Introduction A new type of viral pneumonia cases occurred in Wuhan, Hubei Province in China, on December 31, 2019; named "COVID-19" on January 12, 2020 by the World Health Organization (WHO) [1].
    [Show full text]
  • Lipid Metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives
    cancers Review Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives 1, 1, 1 2 1 Laurence Pellerin y, Lorry Carrié y , Carine Dufau , Laurence Nieto , Bruno Ségui , 1,3 1, , 1, , Thierry Levade , Joëlle Riond * z and Nathalie Andrieu-Abadie * z 1 Centre de Recherches en Cancérologie de Toulouse, Equipe Labellisée Fondation ARC, Université Fédérale de Toulouse Midi-Pyrénées, Université Toulouse III Paul-Sabatier, Inserm 1037, 2 avenue Hubert Curien, tgrCS 53717, 31037 Toulouse CEDEX 1, France; [email protected] (L.P.); [email protected] (L.C.); [email protected] (C.D.); [email protected] (B.S.); [email protected] (T.L.) 2 Institut de Pharmacologie et de Biologie Structurale, CNRS, Université Toulouse III Paul-Sabatier, UMR 5089, 205 Route de Narbonne, 31400 Toulouse, France; [email protected] 3 Laboratoire de Biochimie Métabolique, CHU Toulouse, 31059 Toulouse, France * Correspondence: [email protected] (J.R.); [email protected] (N.A.-A.); Tel.: +33-582-7416-20 (J.R.) These authors contributed equally to this work. y These authors jointly supervised this work. z Received: 15 September 2020; Accepted: 23 October 2020; Published: 27 October 2020 Simple Summary: Melanoma is a devastating skin cancer characterized by an impressive metabolic plasticity. Melanoma cells are able to adapt to the tumor microenvironment by using a variety of fuels that contribute to tumor growth and progression. In this review, the authors summarize the contribution of the lipid metabolic network in melanoma plasticity and aggressiveness, with a particular attention to specific lipid classes such as glycerophospholipids, sphingolipids, sterols and eicosanoids.
    [Show full text]
  • 2019 Annual Report
    2019 Annual Report 1 TABLE OF CONTENTS - 2 DEPARTMENT PHOTO - 3 MISSION - 4 PRIMARY FACULTY PROMOTIONS & DEPARTURES - 5 NEW APPOINTMENTS OF SECONDARY FACULTY-6 SECONDARY FACULTY DEPARTURES – 8 IN MEMORIAM – 9 FACULTY WITH PRIMARY APPOINTMENTS - 10 FACULTY WITH SECONDARY APPOINTMENTS - 21 FACULTY WITH EMERITUS APPOINTMENTS – 31 FACULTY WITH ADJUNCT APPOINTMENTS - 32 ADMINISTRATIVE STAFF - 32 NEW GRADUATE STUDENT CLASS – 33 GRADUATE STUDENTS – 36 GRADUATES– 37 FACULTY HONORS – 39 STUDENT HONORS - 40 PUBLICATIONS - 42 ABSTRACTS - 47 RESEARCH GRANTS ACTIVE - 59 RESEARCH GRANTS SUBMITTED - 68 INVITED SCIENTIFIC PRESENTATIONS - 76 INTELLECTUAL PROPERTY ACTIONS – 80 DEPARTMENTAL COURSES - 81 STANDING COMMITTEES – 82 NCI CANCER EDUCATION PROGRAM - 83 2 3 MISSION The Department of Pharmacology and Toxicology will ensure academic excellence and achievement of regional, national, and international recognition for the quality of its educational, research, and service activities. Guided by the University of Louisville and the School of Medicine Strategic Plans, the mission of the Department of Pharmacology and Toxicology focuses on five broad objectives: • Provide instruction in pharmacology and toxicology of the highest quality for the education and preparation of medical, dental, and other health care professional students. Emphasis is placed on the fundamental principles necessary for life-long learning and the essential knowledge required for rational, effective, and safe use of drug therapy. • Advance biomedical knowledge through high quality research and other scholarly activities, particularly in pharmacology and toxicology and other areas of focus within the University of Louisville and School of Medicine Strategic Plans. • Provide robust research and educational experiences in pharmacology and toxicology for the education and training of future biomedical scientists who will provide and advance biomedical education, research, and service.
    [Show full text]
  • Updates in Hiv Therapeutics and Prevention
    5/17/2018 UPDATES IN HIV THERAPEUTICS AND PREVENTION Sean Kelly, MD Vanderbilt Division of Infectious Diseases May 17, 2018 Agenda • New Agents, Old Classes • Novel Therapies • Updates on long-acting ART • Updates on dual therapy • Updates on adverse events • Prevention/Pre-Exposure Prophylaxis This just in! • Bictegravir/tenofovir alafenamide/emtricitabine • Dolutegravir/rilpivirine • Ibalizumab 1 5/17/2018 New HIV drugs (from existing classes) Doravirine • NNRTI with fewer CNS adverse effects than EFV • Can be used in the setting of the most common NNRTI resistance mutations (K103N, Y181C, G190A) • DRIVE – phase III study • 766 participants randomized to 2 NRTIs + doravirine vs. 2 NRTIs + DVR/r • Doravirine was non-inferior to DRV/r at 48 weeks • Doravirine yielded a more favorable lipid profile than DRV/r Molina JM et al. (Squires K presenting) Doravirine is non-inferior to darunavir/r in phase 3 treatment- naive trial at week 48. Conference on Retroviruses and Opportunistic Infections (CROI 2017), Seattle, abstract 45LB 2017 Doravirine • DRIVE-AHEAD • Phase III study evaluating DOR/TDF/3TC vs TDF/FTC/EFV (Atripla®) in ART-naïve participants • DOR-regimen was non-inferior at 48 weeks • Fewer neuropsychiatric adverse events with DOR-regimen • DRIVE-SHIFT • Phase III study evaluating switch from boosted PI-based regimen to DOR/TDF/3TC • Results pending Squires KE, Molina JM, Sax PE, et al. Fixed dose combination of doravirine/lamivudine/TDF is non-inferior to efavirenz/emtricitabine/TDF in treatment-naïve adults with HIV-1 infection: week 48 results of the Phase 3 DRIVE-AHEAD study. 9th IAS Conference on HIV Science (IAS 2017), July 23- 26, 2017, Paris.
    [Show full text]
  • Quantitative High-Throughput Profiling of Environmental Chemicals and Drugs That Modulate Farnesoid X Receptor
    OPEN Quantitative High-Throughput Profiling of SUBJECT AREAS: Environmental Chemicals and Drugs that SCREENING SMALL MOLECULES Modulate Farnesoid X Receptor Chia-Wen Hsu1, Jinghua Zhao1, Ruili Huang1, Jui-Hua Hsieh2, Jon Hamm3, Xiaoqing Chang3, Keith Houck4 Received & Menghang Xia1 27 June 2014 Accepted 1National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, 2Division of the National 29 August 2014 Toxicology Program, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 3Integrated Laboratory Systems, Inc., Morrisville, NC, 4U.S. Environmental Protection Agency, Research Triangle Park, NC. Published 26 September 2014 The farnesoid X receptor (FXR) regulates the homeostasis of bile acids, lipids, and glucose. Because endogenous chemicals bind and activate FXR, it is important to examine which xenobiotic compounds Correspondence and would disrupt normal receptor function. We used a cell-based human FXR b-lactamase (Bla) reporter gene assay to profile the Tox21 10K compound collection of environmental chemicals and drugs. requests for materials Structure-activity relationships of FXR-active compounds revealed by this screening were then compared should be addressed to against the androgen receptor, estrogen receptor a, peroxisome proliferator-activated receptors d and c, and M.X. ([email protected]. the vitamin D receptor. We identified several FXR-active structural classes including anthracyclines, gov) benzimidazoles, dihydropyridines, pyrethroids, retinoic acids, and vinca alkaloids. Microtubule inhibitors potently decreased FXR reporter gene activity. Pyrethroids specifically antagonized FXR transactivation. Anthracyclines affected reporter activity in all tested assays, suggesting non-specific activity. These results provide important information to prioritize chemicals for further investigation, and suggest possible modes of action of compounds in FXR signaling.
    [Show full text]
  • 1. Endocannabinoid System (ECS)
    UNIVERSITÀ DI PISA Dipartimento di Farmacia Corso di Laurea Specialistica in Chimica e Tecnologia Farmaceutiche Tesi di Laurea: DESIGN AND SYNTHESIS OF HETEROCYCLIC DERIVATIVES AS POTENTIAL MAGL INHIBITORS Relatori: Prof. Marco Macchia Candidato: Glenda Tarchi Prof.ssa Clementina Manera (matricola N° 445314) Dott.ssa Chiara Arena Settore Scientifico Disciplinare: CHIM-08 ANNO ACCADEMICO 2013–2014 INDEX Sommario INDEX ......................................................................................... 3 1. Endocannabinoid system (ECS) ......................................... 6 1.1 Endocannabinoid receptors ........................................................... 7 1.2 Mechanism of endocannabinoid neuronal signaling ..................... 9 1.3 Endocannabinoids biosynthesis ................................................... 11 1.4 Enzymes involved in endocannabinoids degradation ................. 16 1.4.1 FAAH ........................................................................................................ 16 1.4.2 MAGL ....................................................................................................... 18 1.4.3 ABHD6 ..................................................................................................... 20 1.4.4 ABDH12 ................................................................................................... 21 2. MAGL like pharmacological target ................................ 23 2.1 The role of MAGL in pain and inflammation ............................. 24 2.1.1 Relation between
    [Show full text]
  • USP Reference Standards Catalog
    Last Updated On: January 6, 2016 USP Reference Standards Catalog Catalog # Description Current Lot Previous Lot CAS # NDC # Unit Price Special Restriction 1000408 Abacavir Sulfate R028L0 F1L487 (12/16) 188062-50-2 $222.00 (200 mg) 1000419 Abacavir Sulfate F0G248 188062-50-2 $692.00 Racemic (20 mg) (4-[2-amino-6-(cyclo propylamino)-9H-pur in-9yl]-2-cyclopenten e-1-methanol sulfate (2:1)) 1000420 Abacavir Related F1L311 F0H284 (10/13) 124752-25-6 $692.00 Compound A (20 mg) ([4-(2,6-diamino-9H- purin-9-yl)cyclopent- 2-enyl]methanol) 1000437 Abacavir Related F0M143 N/A $692.00 Compound D (20 mg) (N6-Cyclopropyl-9-{( 1R,4S)-4-[(2,5-diami no-6-chlorpyrimidin- 4-yloxy)methyl] cyclopent-2-enyl}-9H -purine-2,6-diamine) 1000441 Abacavir Related F1L318 F0H283 (10/13) N/A $692.00 Compound B (20 mg) ([4-(2,5-diamino-6-c Page 1 Last Updated On: January 6, 2016 USP Reference Standards Catalog Catalog # Description Current Lot Previous Lot CAS # NDC # Unit Price Special Restriction hloropyrimidin-4-yla mino)cyclopent-2-en yl]methanol) 1000452 Abacavir Related F1L322 F0H285 (09/13) 172015-79-1 $692.00 Compound C (20 mg) ([(1S,4R)-4-(2-amino -6-chloro-9H-purin-9 -yl)cyclopent-2-enyl] methanol hydrochloride) 1000485 Abacavir Related R039P0 F0J094 (11/16) N/A $692.00 Compounds Mixture (15 mg) 1000496 Abacavir F0J102 N/A $692.00 Stereoisomers Mixture (15 mg) 1000500 Abacavir System F0J097 N/A $692.00 Suitability Mixture (15 mg) 1000521 Acarbose (200 mg) F0M160 56180-94-0 $222.00 (COLD SHIPMENT REQUIRED) 1000532 Acarbose System F0L204 N/A $692.00 Suitability
    [Show full text]
  • Small Molecules in Solution Has Rarely Been Reported, However, As a General Guide We Recommend Storage in DMSO at -20°C
    (Z)-Guggulsterone Small Molecules Retinoic acid receptor (RAR) pathway inhibitor; Inhibits farnesoid X receptor (FXR) Catalog # 73702 1 mg Product Description (Z)-Guggulsterone is a plant steroid found in the resin of the guggul plant Commiphora mukul that acts as a selective antagonist of farnesoid X receptor (FXR; Cui et al.). It decreases chenodeoxycholic acid (CDCA)-induced FXR activation (IC ₅₀ = 10 µM) in the presence of 100 µM CDCA (Urizar et al.; Cui et al.). Molecular Name: (Z)-Guggulsterone Alternative Names: Not applicable CAS Number: 39025-23-5 Chemical Formula: C₂₁H₂₈O₂ Molecular Weight: 312.5 g/mol Purity: ≥ 95% Chemical Name: (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15- decahydrocyclopenta[a]phenanthrene-3,16-dione Structure: Properties Physical Appearance: A crystalline solid Storage: Product stable at -20°C as supplied. Protect product from prolonged exposure to light. For long-term storage store with a desiccant. For product expiry date, please contact [email protected]. Solubility: · DMSO ≤ 800 µM · Absolute ethanol ≤ 3.2 µM · DMF ≤ 30 mM For example, to prepare a 10 mM stock solution in DMF, resuspend 1 mg in 320 μL of DMF. Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported, however, as a general guide we recommend storage in DMSO at -20°C. Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application. Compound has low solubility in aqueous media.
    [Show full text]